Please login to the form below

Not currently logged in
Email:
Password:

Onyx Health wins two new accounts

Newcells Biotech and HeartScan appoint marketing comms agency

Onyx Health

Onyx Health has been appointed by Newcells Biotech, a group that provides cell-based assays using induced pluripotent stem cell (iPSC) to the global drug and chemical pre-clinical market.

The marketing communications agency will strengthen Newcells’ position in the drug discovery outsourcing market.

Dr Mike Nicholds, chief executive officer at Newcells Biotech, said: “A new drug can take on average over ten years from initial discovery stage to licensing approval with each approved drug costing well in excess of £1bn to develop.

“At Newcells Biotech, our expertise and technology are at the forefront of the sector, and we are confident Onyx Health has the experience to further expand our business in global markets.”

Meanwhile, HeartScan, an echocardiography and sports screening company, has appointed Onyx health to deliver a customer insights strategy.

Dr Antionette Kenny, director at HeartScan, said: “Onyx Health has extensive experience in health screening and access to many of the stakeholders we need to work with.

“They will play an important role to guide and help us grow our business.”

Onyx Health’s clients are based in life science, pharmaceutical, medical devices, diagnostic and consumer health sectors, most of which want to enter global and UK markets.

Karen Winterhalter, health director at Onyx, said: “For some time, Onyx Health has been the agency of choice for healthcare innovators in the North-East, with Newcells Biotech and HeartScan as two perfect examples of this.”

Article by
Gemma Jones

19th October 2017

From: Marketing

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...
Is communication failing us?
Compelling people to care in a world oversaturated with news and information...